Ocular Therapeutics

3 Biotech Stocks That Could Rise 90% or More, According to Wall Street
Motley Fool
Sun, 10/17/21 - 10:57 pm
ChemoCentryx
Ocular Therapeutics
Axsome Therapeutics
FDA rejects Ocular Therapeutix’ Dextenza post-operative pain indication
Mass Device
Tue, 07/26/16 - 11:05 am
FDA
devices
Ocular Therapeutics
Dextenza
post-operative pain
7 Biopharma Companies That Destroyed Shareholders Last Week
24/7 Wall St
Sun, 06/12/16 - 09:52 pm
ProNai
Adamis Pharmaceuticals
Ocular Therapeutics
Mirati Therapeutics
Immunomedics
Valeant Pharmacueticals
Biogen